D-0360-2022 Class II Terminated

Recalled by RemedyRepack Inc. — Indiana, PA

FDA drug recall D-0360-2022 was initiated by RemedyRepack Inc. on Dec 29, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Apr 14, 2022). Affected quantity: a) 716 bottles/ 1432 capsules b) 223 blister packs/ 466 capsules.

Recall details

Product Type
Drugs
Report Date
Jan 12, 2022
Initiation Date
Dec 29, 2021
Termination Date
Apr 14, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 716 bottles/ 1432 capsules b) 223 blister packs/ 466 capsules

Product description

Cefixime 400 mg capsule, packaged in a) 2-count bottle (NDC 70518-2749-02), b) 2-count blister pack (NDC 70518-2749-03), Rx only, MFG: Ascend Labs, LLC, Montvale, NJ 07645

Reason for recall

Failed Impurities/Degradation Specifications

Distribution pattern

Product was distributed to two direct accounts in MI and PA.

Code information

Lot #: a) B1429436-110821, Exp 07/2022; B1429434-110821, Exp 11/2022; B1429435-110821, Exp 11/2022; B1279449-072021, Exp 07/2022; B1279457-072021, Exp 07/2022; B1279442-072021,Exp 07/2022; B1057718-012621, Exp 01/2022; B1057727-012621, Exp 01/2022; b) B1358139-092121, Exp 03/2022; B1424654-110421, B1437578-111421, Exp 05/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0360-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0360-2022. Report a data issue: hello@regdatalab.com.